

APPENDIX A

Eligibility of Drugs for Extended Drug Supply

Eligibility of Drugs for Extended Drug Supply			
Maximum Extended Supply	Cancer Drugs Eligible for Extended Supply (*providing conditions in policy are met)		Cancer Drugs NOT Eligible for Extended Supply (beyond 1 cycle or 1 month)
Two (2) Months	abemaciclib	lapatinib	cyclophosphamide
	afatinib	larotrectinib	etoposide
	alectinib	lenvatinib	fludarabine
	asciminib	lorlatinib	lomustine
	axitinib	niraparib	melphalan
	azacitidine (Onureg®)	niraparib/abiraterone	mercaptopurine
	belzutifan	olaparib	procarbazine
	brigatinib	osimertinib	regorafenib
	cabozantinib	palbociclib	sorafenib
	capecitabine	pegylated interferon	temozolomide
	capivasertib	pomalidomide	thioguanine
	ceritinib	ponatinib	tretinoin
	crizotinib	ribociclib	
	dabrafenib +/- trametinib	ripretinib	
	decitabine/cedazuridine (Inqovi®)	selinexor	
	encorafenib +/- binimetinib	selpercatinib	
	entrectinib	trametinib +/- dabrafenib	
	erlotinib	trifluridine-tipiracil	
	everolimus	vandetanib	
	gefitinib	vemurafenib +/- cobimetinib	
	gilteritinib		
Three (3) Months (**restricted to maximum 84 day supply through Health Canada regulated safety programs)	acalabrutinib	medroxyprogesterone	Any drug given intravenously that requires administration within a treatment centre will not be provided or dispensed to patients for reasons of extended absence from the province.
	abiraterone	megestrol acetate	
	acitretin	memantine	
	apalutamide	methotrexate	
	clodronate	mitotane	
	darbepoetin	pazopanib	
	darolutamide	relugolix	
	denosumab	ruxolitinib	
	enzalutamide	sunitinib	
	fedratinib	venetoclax	
	ibrutinib	** vismodegib	
	idelalisib	zanubrutinib	
	**lenalidomide		
	Four (4) Months	bosutinib	
chlorambucil			
nilotinib			
Six (6) Months	anagrelide	goserelin (Zoladex LA®)	
	anastrozole	hydroxyurea	
	bicalutamide	imatinib	
	cyproterone	lanreotide (Somatuline Autogel®)	
	dasatinib	letrozole	
	degarelix (Firmagon®)	leuprolide (Eligard® or Lupron®)	
	exemestane	octreotide LAR	
	flutamide	tamoxifen	
	fulvestrant		
			Updated June 18, 2025